Evaluate FDMT stock safety — financial health, volatility, institutional backing, and risk factors.

What are the risks of investing in FDMT? | Glauxie AI

Q: What are the risks of investing in FDMT?

4D Molecular Therapeutics, Inc. (FDMT) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO David H. Kirn. 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product... Employees: 40,000.

Q: How much debt does FDMT have?

Review FDMT total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Q: Is FDMT a good long-term investment?

Evaluate FDMT as a long-term investment using fundamental scores, growth metrics, and risk assessment.

What are the risks of investing in FDMT?

🦉

4D Molecular Therapeutics, Inc. (FDMT)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEODavid H. Kirn

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has...

Key Executives

Name	Title
An Song	Chief Translational Medicine Advisor
Ashoo Gupta	Principal Accounting Officer & Principal Financial Officer
David H. Kirn	Co-Founder, President, CEO & Director
Fariborz Kamal	Chief Technical Advisor
John F. Milligan	Executive Chairman
Julian Pei	Head of Investor Relations & Corporate Finance

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

FDMT Profile Financials

Is FDMT stock safe? How much debt does FDMT have? Is FDMT a good long-term investment?